Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.

An S De Vriese, Rogier Caluwé, Lotte Pyfferoen, Dirk De Bacquer, Koen De Boeck, Joost Delanote, Didier De Surgeloose, Piet Van Hoenacker, Bruno Van Vlem, Francis Verbeke

January 2020

Synopsis of Social media discussions

Discussions highlight the study's investigation of rivaroxaban versus warfarin and the role of vitamin K2, with comments reflecting both curiosity and critique, such as noting the 'failed' outcomes and questioning the transformative potential of these strategies. The tone suggests a thoughtful engagement with the research's nuances and implications for clinical practice.

A
Agreement
 Moderate agreement

Most discussions recognize the study's findings, especially the limited impact of vitamin K2 on vascular calcification, showing general agreement.

I
Interest
 High level of interest

The complex topic of anticoagulation in dialysis patients generates high curiosity, with many referencing detailed trial results.

E
Engagement
 High engagement

Comments include references to methodology, past studies, and implications for clinical practice, indicating deep involvement.

I
Impact
 Moderate level of impact

While some see the study as insightful, there is a shared view that its findings may modestly influence current treatment approaches in this patient group.

Social Mentions

YouTube

2 Videos

Facebook

2 Posts

Twitter

46 Posts

Blogs

2 Articles

Metrics

Video Views

6,029

Total Likes

117

Extended Reach

142,063

Social Features

52

Timeline: Posts about article

Top Social Media Posts

Posts referencing the article

2023 Nephrology and Hypertensiology Advances by Leading Experts

2023 Nephrology and Hypertensiology Advances by Leading Experts

In this review of 2023, experts discuss the top nephrological and hypertensiological studies, including the impact of high-efficiency hemodiafiltration on mortality and the safety of anticoagulant switching in frail patients.

MARKUS at HOMe

December 22, 2023

3,374 views

Comparing Anticoagulants in CKD Patients with Atrial Fibrillation

Comparing Anticoagulants in CKD Patients with Atrial Fibrillation

Prof. An de Vriese discusses the pros and cons of oral anticoagulation in chronic kidney disease patients with atrial fibrillation. The focus is on a study comparing vitamin K antagonists and rivaroxaban, highlighting their safety and efficacy in this unique patient group.

MARKUS at HOMe

March 11, 2022

2,295 views

Exploring Vitamin K2: Effects on Bone and Heart Health

Exploring Vitamin K2: Effects on Bone and Heart Health

In this video, I dive deep into the science behind Vitamin K2 and its impact on bone health and heart health. I will unpack its key functions, including maintaining bone health and preventing arterial calcium buildup, based on the latest research and my professional experience.

Tawnya Hansen

July 2, 2024

360 views

  • Gunnar Henrik Heine
    @gunnar_heine (Twitter)

    @sarah_halmer @AKronbichler @Cihan_Ay_MD @m_windp @AntMarlies @oegnephro @fervenzafernan1 @PfallerBirgit @HerrmannMd @IngoEitel and in the meantime re-listen to Dr de Vriese's ideas at https://t.co/HvadGUQfZ0
    view full post

    May 10, 2024

    1

  • Gunnar Henrik Heine
    @gunnar_heine (Twitter)

    #WorldStrokeDay 2023 - here comes our 2022 discussion on Anticoagulation & Atrial Fibrillation in CKD - VALKYRIE with An de Vriese with @StephanSchirme2 and @AntMarlies (Partner @oegnephro @dgfn_ev @com_SFNDT) https://t.co/pXY0kZxEre via @YouTube
    view full post

    October 29, 2023

    2

  • Ahmad Masri
    @MasriAhmadMD (Twitter)

    @mbelshazly @Hragy @Bloodman Yes they were testing the vit K hypothesis See their earlier pub https://t.co/EaUN6jNvyY
    view full post

    March 22, 2021

    3

  • renalRCTs
    @renalRCTs (Twitter)

    Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study. https://t.co/Em2DkBKPNY https://t.co/VTdjoG1P0L
    view full post

    July 17, 2020

  • Trip Primary Care
    @TripPrimaryCare (Twitter)

    New2Trip: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban w/ or without Vitamin K2 in Hemodialysis Patients w/ Atrial Fibrillation: Valkyrie Study https://t.co/y9bGEjnl07
    view full post

    March 12, 2020

  • Trip Primary Care
    @TripPrimaryCare (Twitter)

    New2Trip: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban w/ or without Vitamin K2 in Hemodialysis Patients w/ Atrial Fibrillation: Valkyrie Study https://t.co/y9bGEjnl07
    view full post

    March 9, 2020

  • Trip Primary Care
    @TripPrimaryCare (Twitter)

    New2Trip: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban w/ or without Vitamin K2 in Hemodialysis Patients w/ Atrial Fibrillation: Valkyrie Study https://t.co/y9bGEjnl07
    view full post

    March 7, 2020

  • Trip Database
    @tripdatabase (Twitter)

    New2Trip: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban w/ or without Vitamin K2 in Hemodialysis Patients w/ Atrial Fibrillation: Valkyrie Study https://t.co/jikLmgivR3
    view full post

    March 7, 2020

  • Trip Primary Care
    @TripPrimaryCare (Twitter)

    New2Trip: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban w/ or without Vitamin K2 in Hemodialysis Patients w/ Atrial Fibrillation: Valkyrie Study https://t.co/y9bGEjEVRF
    view full post

    March 5, 2020

    1

  • Trip Primary Care
    @TripPrimaryCare (Twitter)

    New2Trip: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban w/ or without Vitamin K2 in Hemodialysis Patients w/ Atrial Fibrillation: Valkyrie Study https://t.co/y9bGEjnl07
    view full post

    March 1, 2020

  • Trip Database
    @tripdatabase (Twitter)

    New2Trip: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban w/ or without Vitamin K2 in Hemodialysis Patients w/ Atrial Fibrillation: Valkyrie Study https://t.co/jikLmgivR3
    view full post

    March 1, 2020

  • Trip Primary Care
    @TripPrimaryCare (Twitter)

    New2Trip: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban w/ or without Vitamin K2 in Hemodialysis Patients w/ Atrial Fibrillation: Valkyrie Study https://t.co/y9bGEjnl07
    view full post

    February 28, 2020

  • Trip Primary Care
    @TripPrimaryCare (Twitter)

    New2Trip: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban w/ or without Vitamin K2 in Hemodialysis Patients w/ Atrial Fibrillation: Valkyrie Study https://t.co/y9bGEjnl07
    view full post

    February 26, 2020

  • Trip Primary Care
    @TripPrimaryCare (Twitter)

    New2Trip: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban w/ or without Vitamin K2 in Hemodialysis Patients w/ Atrial Fibrillation: Valkyrie Study https://t.co/y9bGEjnl07
    view full post

    February 23, 2020

  • Trip Primary Care
    @TripPrimaryCare (Twitter)

    New2Trip: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban w/ or without Vitamin K2 in Hemodialysis Patients w/ Atrial Fibrillation: Valkyrie Study https://t.co/y9bGEjnl07
    view full post

    February 21, 2020

  • Trip Database
    @tripdatabase (Twitter)

    New2Trip: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban w/ or without Vitamin K2 in Hemodialysis Patients w/ Atrial Fibrillation: Valkyrie Study https://t.co/jikLmgivR3
    view full post

    February 21, 2020

  • Trip Primary Care
    @TripPrimaryCare (Twitter)

    New2Trip: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban w/ or without Vitamin K2 in Hemodialysis Patients w/ Atrial Fibrillation: Valkyrie Study https://t.co/y9bGEjnl07
    view full post

    February 19, 2020

  • Fran Nuñez Valverde
    @fmnv71 (Twitter)

    RT @Manugrillo2: Clinical Research Restricted Access Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by #Riva…
    view full post

    February 3, 2020

    1

  • Manu Morales Sánchez
    @Manugrillo2 (Twitter)

    Clinical Research Restricted Access Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by #Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study https://t.co/UWhJQ2wmQw
    view full post

    February 3, 2020

    1

    1

  • Luis Gómez
    @lbgm1983 (Twitter)

    RT @JonathanNefro: En pacientes en hemodiálisis y ANTICOAGULADOS con RIVAROXABAN o WARFARINA por fibrilación auricular, la administración d…
    view full post

    February 2, 2020

    11

  • Mel Tapia
    @7Melkin (Twitter)

    RT @JonathanNefro: En pacientes en hemodiálisis y ANTICOAGULADOS con RIVAROXABAN o WARFARINA por fibrilación auricular, la administración d…
    view full post

    February 1, 2020

    11

  • Dr. Ronald Caraballo NEFROLOGO
    @ronald_nefro (Twitter)

    RT @JonathanNefro: En pacientes en hemodiálisis y ANTICOAGULADOS con RIVAROXABAN o WARFARINA por fibrilación auricular, la administración d…
    view full post

    January 29, 2020

    11

  • Alanepe
    @Alanepe1 (Twitter)

    RT @JonathanNefro: En pacientes en hemodiálisis y ANTICOAGULADOS con RIVAROXABAN o WARFARINA por fibrilación auricular, la administración d…
    view full post

    January 29, 2020

    11

  • Anace Pastor ✨️ Renalis
    @anace710 (Twitter)

    RT @JonathanNefro: En pacientes en hemodiálisis y ANTICOAGULADOS con RIVAROXABAN o WARFARINA por fibrilación auricular, la administración d…
    view full post

    January 29, 2020

    11

  • Gustavo A. Bautista
    @metanefro (Twitter)

    RT @JonathanNefro: En pacientes en hemodiálisis y ANTICOAGULADOS con RIVAROXABAN o WARFARINA por fibrilación auricular, la administración d…
    view full post

    January 29, 2020

    11

  • fausto heredia z.
    @drfherediaz (Twitter)

    RT @JonathanNefro: En pacientes en hemodiálisis y ANTICOAGULADOS con RIVAROXABAN o WARFARINA por fibrilación auricular, la administración d…
    view full post

    January 29, 2020

    11

  • Ricardo Orozco C.
    @Dr_Orozco_Nefro (Twitter)

    RT @JonathanNefro: En pacientes en hemodiálisis y ANTICOAGULADOS con RIVAROXABAN o WARFARINA por fibrilación auricular, la administración d…
    view full post

    January 29, 2020

    11

  • javier rodriguez
    @javier_rdgz (Twitter)

    RT @JonathanNefro: En pacientes en hemodiálisis y ANTICOAGULADOS con RIVAROXABAN o WARFARINA por fibrilación auricular, la administración d…
    view full post

    January 29, 2020

    11

  • Jonathan Chávez
    @JonathanNefro (Twitter)

    En pacientes en hemodiálisis y ANTICOAGULADOS con RIVAROXABAN o WARFARINA por fibrilación auricular, la administración de VITAMINA K no disminuyó los puntajes de CALCIFICACIÓN VASCULAR En el ensayo clínico VALKIRIE, otro más fallido
    view full post

    January 29, 2020

    26

    11

  • Mehdi Maanaoui
    @MaanaouiMehdi (Twitter)

    Ballsy haha rivaroxaban in dialysis patients, safe and efficient? Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study https://t.co/MKytVBPN9R
    view full post

    November 15, 2019

    1

  • renalRCTs
    @renalRCTs (Twitter)

    Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study. https://t.co/XlBTHFHTk6
    view full post

    November 11, 2019

  • Ana Maria Matias
    @AMCMA6 (Twitter)

    RT @JASN_News: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hem…
    view full post

    November 10, 2019

    14

  • MousTapha Faye
    @MF_NephroEpi (Twitter)

    RT @JASN_News: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hem…
    view full post

    November 9, 2019

    14

  • Miguel Guillen 140#
    @AnayaGuillen (Twitter)

    RT @JASN_News: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hem…
    view full post

    November 9, 2019

    14

  • Ahmed Tall
    @ahmedtall35 (Twitter)

    RT @JASN_News: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hem…
    view full post

    November 9, 2019

    14

  • BVNSBN
    @BSNrenal (Twitter)

    RT @JASN_News: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hem…
    view full post

    November 9, 2019

    14

  • MyintZu Aung
    @MyintZuAung1 (Twitter)

    RT @JASN_News: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hem…
    view full post

    November 9, 2019

    14

  • Tanganxoan
    @Tangan_zuan (Twitter)

    RT @JASN_News: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hem…
    view full post

    November 9, 2019

    14

  • thomas robert
    @nephrobug (Twitter)

    RT @JASN_News: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hem…
    view full post

    November 9, 2019

    14

  • bruno van vlem
    @brunovanvlem (Twitter)

    RT @JASN_News: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hem…
    view full post

    November 9, 2019

    14

  • Paula Duran
    @PaulaDu88412761 (Twitter)

    RT @JASN_News: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hem…
    view full post

    November 9, 2019

    14

  • AnitaN189
    @AnitaFanse80 (Twitter)

    RT @JASN_News: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hem…
    view full post

    November 9, 2019

    14

  • Sinead Stoneman
    @Stones__ (Twitter)

    RT @JASN_News: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hem…
    view full post

    November 9, 2019

    14

  • Zoran Paunic
    @unicipa (Twitter)

    RT @JASN_News: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hem…
    view full post

    November 9, 2019

    14

  • Rogier Caluwé
    @RogierCaluwe (Twitter)

    RT @JASN_News: Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hem…
    view full post

    November 9, 2019

    14

  • JASN_News
    @JASN_News (Twitter)

    Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study @RogierCaluwe https://t.co/FXmt0qHjCX https://t.co/S5ty2uOHxw
    view full post

    November 9, 2019

    19

    14

Abstract Synopsis

  • The study investigated how replacing Vitamin K antagonists (VKAs) with rivaroxaban, with or without vitamin K2, affects vascular calcification (VC) and health outcomes in hemodialysis patients with atrial fibrillation.
  • Results showed that while baseline vitamin K deficiency was common and VKAs worsened vitamin K deficiency (indicated by increased dpucMGP levels), there was no significant difference in VC progression or cardiovascular events across treatment groups, although rivaroxaban was associated with fewer severe bleeding episodes.
  • Supplementing with vitamin K2 alongside rivaroxaban improved vitamin K status but did not significantly slow VC progression, suggesting that while changing anticoagulation strategies may improve vitamin K levels and reduce bleeding risks, they do not markedly impact vascular calcification in this patient population.